Colombia exports its CBD to Switzerland

Medical cannabis producer PharmaCielo has completed its first commercial export CBD isolate from Colombia to Europe, after the shipment arrived safely in Switzerland. CBD isolate is an essential ingredient in various therapeutic products, such as nutraceuticals, topicals, and cannabis-derived products, most of which are legal in Europe. The shipment was delivered to the Swiss headquarters of Creso Pharma, an Australian pharmaceutical group with extensive expertise in cannabis and hemp-derived products for human and veterinary use.

PharmaCielo is headquartered in Ontario, Canada, but the company is Colombia’s largest producer of medical cannabis oil. The Colombian government has granted PharmaCielo the first export license of commercial CBD isolate on July 25, 2019. «This shipment is symbolic in many ways,’ said David Attard, CEO of PharmaCielo Ltd. «PharmaCielo is the first medical cannabis company to commercially export cannabis-derived isolates from Colombia to Switzerland, which is the global capital of the pharmaceutical industry.».

Attard also said he was «particularly pleased» that the first shipment was being made in partnership with Cresco Pharma, since the Australian pharmaceutical company is in the process of being acquired for 122 million Australian dollars. Its board of directors has approved the takeover by PharmaCielo, and the change in management is scheduled for next month.

The collaboration between PharmaCielo and Creso Pharma extends beyond the current and future supply of cannabis isolates and oil extracts. PharmaCielo recently announced a multi-country sales agreement with Uruguay-based Laboratorios Adler, under which it will supply the isolate of CBD manufactured by PharmaCielo, as well as Creso Pharma’s line of veterinary CBD dietary supplements in Adler, for distribution in Uruguay, Paraguay, Bolivia, and southern Brazil.